Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Passes The Buck On LDTs, But Floats Ideas

Executive Summary

The US agency has backed away from its intent to oversee laboratory-developed tests as set out in a controversial 2014 draft guidance. Instead, in a new discussion paper it is advising legislation to handle the issue. The agency also urges LDT developers to consider recommendations to increase transparency.


Related Content

A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews
House Appropriators Will Tell US FDA 'Don't Finalize' LDT Guidance In 2018 Funding Bill
Gottlieb Wants Timely Approval Of User Fee Bill, Balanced LDT Plan
Lab Professionals Oppose Draft Dx Reform Bill; Lab, IVD Industry Ready To Work With Congress
Drug Development, Not Conflicts, Dominates Gottlieb's Confirmation Hearing
Diagnostics Reg Overhaul Floated In US House
Device User-Fee Agreement Gets A Senate Hearing
FDA's Document Dump: Guidance Release Skyrocketed In Advance Of Trump
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
FDA Provides Accessories Guidance, But May Be 'Missed' Opportunity





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts